# Lukas Bubendorf

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lukas-bubendorf/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,665 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 84 |
| i10-index | 272 |
| Last Known Institution | University of Basel |
| OpenAlex ID | https://openalex.org/A5000570624 |
| ORCID iD | https://orcid.org/0000-0001-5970-1803 |
| Works | 645 |

## Researcher papers

- [PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project](https://scholariq.org/papers/pd-l1-immunohistochemistry-comparability-study-in-real-life-clinical-samples/)
- [A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee](https://scholariq.org/papers/a-grading-system-for-invasive-pulmonary-adenocarcinoma-a-proposal-from-the/)
- [2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up](https://scholariq.org/papers/2nd-esmo-consensus-conference-on-lung-cancer-early-stage-non-small-cell-lung/)
- [IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy](https://scholariq.org/papers/iaslc-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer/)
- [Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer](https://scholariq.org/papers/best-practices-recommendations-for-diagnostic-immunohistochemistry-in-lung/)
- [PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee](https://scholariq.org/papers/pd-l1-testing-for-lung-cancer-in-2019-perspective-from-the-iaslc-pathology/)
- [Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer](https://scholariq.org/papers/second-esmo-consensus-conference-on-lung-cancer-pathology-and-molecular/)
- [The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee](https://scholariq.org/papers/the-promises-and-challenges-of-tumor-mutation-burden-as-an-immunotherapy/)
- [Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers](https://scholariq.org/papers/trastuzumab-emtansine-t-dm1-in-patients-with-previously-treated-her2/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [University of Basel](https://scholariq.org/institutions/university-of-basel/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.